If you think speaking English is enough to succeed in Japan, think again. Many European and North American pharma executives—especially those at CDMOs or mid‑sized firms—enter Japan with confidence. They bring English‑speaking reps, polished slides, and strong tech. Yet despite initial enthusiasm, meetings stall, deals fade, and progress grinds to Read more
What we learned by doing it ourselves — and why it’s only possible with local expertise “We Thought It Would Be Impossible. It Wasn’t — But Only Because We Knew the Terrain.” When we set out to establish a fully licensed MAH (Marketing Authorization Holder) in Japan — from scratch Read more
If you’re in business development at a CDMO in Europe or North America, chances are CPhI Japan is the first event that comes to mind when exploring the Japanese pharmaceutical market. And on the surface, it makes sense: CPhI has global name recognition, and Japan is the world’s third-largest pharma Read more
Expanding into the Japanese pharmaceutical market presents a wealth of opportunities for foreign companies, but it also comes with unique challenges. Regulatory complexities, language barriers, and the need for local expertise make market entry a daunting process. We have recently obtained MAH license for a licent, and would like to Read more
For non-Japanese biopharmaceutical companies looking to enter the Japanese market, the first challenge is often finding a comprehensive list of biopharma companies in Japan. While big names like Takeda or Astellas are well-known globally, many smaller, innovative players remain under the radar. These small-to-mid-size companies can offer unique partnership opportunities, Read more